|
|
|
| First Name: | David | | Last Name: | Small | | Title: | Professorial Research Fellow | | Advanced Degrees: | BSc. PhD. | | Affiliation: | University of Tasmania | | Department: | Menzies Research Institute | | Street Address 1: | Private Bag 23 | | City: | Hobart | | State/Province: | Tasmania | | Zip/Postal Code: | 7001 | Country/Territory: | Australia | | Phone: | 61-3-6226-7700 | | Fax: | 61-3-6226-7704 | | Email Address: |  |
Disclosure:
(view policy)
|
|
|
|
View all comments by David Small
|
Alzheimer Disease, Aging Process, Neuromuscular Disorders (ALS, etc.), Tauopathies, Neurodevelopmental Disorders (Down syndrome, etc.), Stroke and Trauma, Polyglutamine Disorders (Huntington's, etc.), Prion Diseases
|
Protein structure/chemistry, Proteomics, Diagnosis, Neurobiology, A-beta PP/A-beta, Molecular and Cell biology
|
University, Research institute
|
PhD University of Melbourne, Australia, 1982.
Postdoctoral research, MIT 1982-1984, Flinders University of South Australia, 1984-1985.
University of Melbourne 1986-2002. Monash University 2003-present. Current appointment National Health and Medical Research Council of Australia Senior Research Fellow (Continuing) Level B. Approximately 110 publications (mostly in field of Alzheimer's disease and related disorders) as of 2003. |
1. Small, D.H., Nurcombe, V., Clarris, H., Beyreuther, K. & Masters, C.L. (1994) A heparin-binding domain on the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neuroscience 14, 2117-2127.
2. Small, D.H., Reed, G., Whitefield, B., Nurcombe, V. (1995) Cholinergic regulation of neurite outgrowth from isolated chick sympathetic neurons in culture. J. Neuroscience 15, 144-151.
3. Williamson, T., Mok, S.S., Henry, A., Cappai, R., Lander, A., Nurcombe, V., Beyreuther, K., Masters, C. and Small, D.H. (1996) Secreted glypican binds to the amyloid protein precursor (APP) of Alzheimer’s disease and inhibits APP-induced neurite outgrowth. J. Biol. Chem. 271, 31215-31221.
4. Mok, S.S., Evin, G., Li, Q.X., Smith, A.I., Beyreuther, K., Masters, C.L. and Small, D.H. (1997) A novel metalloprotease in rat brain cleaves the amyloid protein precursor of Alzheimer’s disease generating amyloidogenic fragments. Biochemistry 36, 156-163.
5. Sberna, G., Sáez-Valero, J., Beyreuther, K., Masters, C.L. and Small, D.H. (1997) The amyloid-b protein of Alzheimer’s disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells J. Neurochem. 69, 1177-1184.
6. Sáez-Valero, J., Sberna, G., McLean, C.A., Masters, C.L. and Small, D.H. (1997) Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer’s disease. Lancet 350, 929.
7. Sberna G., Sáez-Valero, J., Li, Q.-X., Czech, C., Beyreuther, K., McLean, C., Masters, C.L. and Small, D.H. (1998) Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the b-amyloid protein precursor of Alzheimer’s disease. J. Neurochem. 71, 723-731.
8. Small, D.H., Mok, S.S. and Bornstein, J.C. (2001) Alzheimer’s disease and Ab toxicity: from top to bottom. Nature Reviews Neuroscience 2, 595-598.
9. Nunan, J., Shearman, M.S., Checler, F., Cappai, R., Evin, G., Beyreuther, K., Masters, C.L. and Small, D.H. (2001) The C-terminal fragment of the Alzheimer’s disease amyloid protein precursor (APP-CTFb) is degraded by a proteasome-dependent mechanism distinct from g-secretase. Eur. J. Biochem. 268, 5329-5336.
10. Subasinghe, S., Unabia, S., Barrow, C.J., Mok, S.S., Aguilar, M.I. and Small, D.H. (2003) Cholesterol is necessary both for the toxic effect of Ab peptides on vascular smooth muscle cells and for Ab binding to vascular smooth muscle cell membranes. J. Neurochem. 84, 471-479.
|
Our understanding of the mechanism of Abeta toxicity. |
We are currently pursuing them. |
That Alzheimer's disease is in essence a disease of altered synaptic plasticity. |
There is no one single piece of evidence. |
|
|
Home
